Published: Apr 29, 2021
Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021
PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE)
Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it was granted a non-dilutive funding of €980,000 from the public investment bank BPI France’s DeepTech program, for its MACA program of Macuneos (BIO201) in dry Age-Related Macular Degeneration (AMD).
The DeepTech program aims to boost highly innovative and breakthrough projects emerging from fundamental research with attractive dedicated financing tools. The funding consists of a conditional advance of €600,000 and a grant of €380,000 which wi
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos .
BIOPHYTIS SAApril 29, 2021 GMT DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potential
Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021
PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it was granted a non-dilutive funding of €980,000 from the public investment bank BPI France’s DeepTech program, for its MACA program of Mac
Form 6-K Biophytis SA For: Apr 26 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021
April 26, 2021 02:00 ET | Source: BIOPHYTIS SA BIOPHYTIS SA Romainville, FRANCE
PARIS and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today provides updates and perspectives on its Sarconeos (BIO101) programs ahead of its upcoming General Assembly on April 26, 2021.
The COVA phase 2-3 study against COVID-19:
Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.